CureVac (NASDAQ:CVAC - Get Free Report)'s stock price was up 5.7% during trading on Friday . The stock traded as high as $4.52 and last traded at $4.47. Approximately 876,726 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 2,196,451 shares. The stock had previously closed at $4.23.
Analysts Set New Price Targets
Separately, JMP Securities reaffirmed a "market outperform" rating and issued a $16.00 price objective on shares of CureVac in a research note on Monday, September 16th.
Get Our Latest Stock Report on CVAC
CureVac Stock Down 0.5 %
The stock's 50-day moving average is $3.06 and its 200-day moving average is $3.14. The company has a market cap of $942.53 million, a price-to-earnings ratio of 7.65, a P/E/G ratio of 0.24 and a beta of 2.50. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. Signaturefd LLC increased its position in shares of CureVac by 26.9% during the third quarter. Signaturefd LLC now owns 27,970 shares of the company's stock worth $82,000 after acquiring an additional 5,927 shares in the last quarter. Green Alpha Advisors LLC increased its holdings in CureVac by 41.3% during the 3rd quarter. Green Alpha Advisors LLC now owns 27,319 shares of the company's stock worth $80,000 after purchasing an additional 7,979 shares in the last quarter. Ballentine Partners LLC raised its stake in shares of CureVac by 58.6% in the third quarter. Ballentine Partners LLC now owns 22,755 shares of the company's stock worth $67,000 after purchasing an additional 8,406 shares during the last quarter. Private Advisor Group LLC purchased a new stake in shares of CureVac in the third quarter worth approximately $30,000. Finally, International Assets Investment Management LLC bought a new position in shares of CureVac in the third quarter valued at approximately $35,000. Institutional investors and hedge funds own 17.26% of the company's stock.
About CureVac
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Further Reading
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
